Patel Sharvil, Ballout Mahmoud, Khan Sandus, Robinson Shane, Adams Alex M, Rynarzewska Ania, Delzell John E
Internal Medicine Department, Northeast Georgia Medical Center, Gainesville, GA, USA.
GME Research, Northeast Georgia Medical Center, Gainesville, GA, USA.
Cardiol Res. 2024 Aug;15(4):275-280. doi: 10.14740/cr1688. Epub 2024 Aug 20.
Coronavirus disease 2019 (COVID-19) infection is associated with proinflammatory states and adverse health outcomes such as ST-segment elevation myocardial infarction (STEMI) and cerebrovascular accidents (CVA). Limited evidence suggests that COVID-19 vaccination may decrease the adverse impact of COVID-19 infections. This study was designed to determine if patients who received COVID-19 vaccination had lower mortality from STEMI and CVA.
This is a retrospective comparative analysis of 3,050 patients, who were admitted to the hospital and diagnosed with STEMI or CVA between April 1, 2019, and April 1, 2022. Patients were divided into three different timeframes: pre-COVID (April 1, 2019, to March 31, 2020), COVID (April 1, 2020 to March 31, 2021), and post-COVID (April 1, 2021 to March 31, 2022). Chi-square analysis was completed to analyze associations between STEMI, CVA, and vaccination status. A multinominal logistic regression was used to determine significant predictors for in-hospital mortality.
A total of 3,050 patients were admitted (1,873 STEMI and 1,177 CVA). STEMI accounted for about 60% of cases in each of the three time periods. There was no statistical difference in STEMI or CVA percentages in the three time periods. There was increased mortality in STEMI and CVA patients (odds ratio (OR) = 11.4; P < 0.001), but patients who received the COVID-19 vaccine were less likely to die (OR = 0.51, 95% confidence interval (CI): 0.28 - 0.93; P < 0.027) when compared to those who were unvaccinated. There was increased risk of death in patients with atrial fibrillation (AFIB) (OR = 2.43; P < 0.001) and chronic heart failure (CHF) (OR = 1.76; P = 0.004). There was increased mortality risk associated with age (OR =1.03; P = 0.001). Patients with coronary artery disease (CAD) (OR = 0.45; P = 0.014) and hyperlipidemia (OR = 0.29; P < 0.001) were less likely to die.
Vaccination against COVID-19 was associated with reduced mortality rates in patients hospitalized with STEMI and CVA. Patients with pre-existing cardiovascular comorbidities such as CAD and hyperlipidemia also had lower mortality.
2019冠状病毒病(COVID-19)感染与促炎状态及不良健康结局相关,如ST段抬高型心肌梗死(STEMI)和脑血管意外(CVA)。有限的证据表明,COVID-19疫苗接种可能会降低COVID-19感染的不良影响。本研究旨在确定接种COVID-19疫苗的患者因STEMI和CVA导致的死亡率是否更低。
这是一项对3050例患者的回顾性比较分析,这些患者于2019年4月1日至2022年4月1日期间入院并被诊断为STEMI或CVA。患者被分为三个不同时间段:COVID-19之前(2019年4月1日至2020年3月31日)、COVID-19期间(2020年4月1日至2021年3月31日)和COVID-19之后(2021年4月1日至2022年3月31日)。采用卡方分析来分析STEMI、CVA与疫苗接种状态之间的关联。使用多项逻辑回归来确定住院死亡率的显著预测因素。
共收治3050例患者(1873例STEMI和1177例CVA)。在三个时间段中,每个时间段STEMI病例约占60%。三个时间段内STEMI或CVA的百分比无统计学差异。STEMI和CVA患者的死亡率有所增加(优势比(OR)=11.4;P<0.001),但与未接种疫苗的患者相比,接种COVID-19疫苗的患者死亡可能性较小(OR=0.51,95%置信区间(CI):0.28 - 0.93;P<0.027)。房颤(AFIB)患者(OR=2.43;P<0.001)和慢性心力衰竭(CHF)患者(OR=1.76;P=0.004)的死亡风险增加。死亡风险与年龄相关(OR=1.03;P=0.001)。冠心病(CAD)患者(OR=0.45;P=0.014)和高脂血症患者(OR=0.29;P<0.